HTN: Diet Patterns (2015)
To compare the effects on BP and vascular compliance of a low sodium-DASH, low-acid-load diet with reference to healthy diet in menopausal or post-menopausal women with BP levels at the upper end of the normal-range BP.
- Experiencing menopausal symptoms
- Had passed through menopause and were not taking hormone replacement therapy
- BMI between 16kg/m2 and 35kg/m2
- Seated systolic blood pressure (SBP) 120mm Hg or more and less than 160mm Hg and diastolic blood pressure (DBP) 80mm Hg or more and less than 95mm Hg at screeening
- A home SBP 116mm Hg or higher or DBP 78mm Hg or higher (using an average of seven days) before randomization
- A clinical diagnosis of hypertension and taking anti-hypertensive medication/therapy (AHT).
- Low or normal BP
- Experienced menopause before turning 43 years old
- Taking warfarin, diphenylhydantoin or medications for osteoporosis treatment such as biphosphonates
- Had been treated for cancer within the past three years
- Had a cardiovascular event in the past six months
- Had insulin-dependent diabetes
- Consumed more than 30 standard alcoholic drinks per week
- Ate main meals outside the home more than twice per week.
Recruitment
The subjects were recruited from the general community.
Design
Randomized parallel dietary intervention.
Intervention
- Subjects were randomly assigned one of the diet groups:
- Vitality (VD): DASH-type diet low-dietary-acid load that contained 100g of cooked red meat per week and maximum of four servings of bread and cereals
- Reference Healthy Diet (RHD) consisting of general dietary guidelines to reduce fat intake and increase intake of breads and cereals (minimum of four servings per day) for 14 weeks
- Both diets were designed to provide adequate calcium (1,000mg per day), with at least three servings per day of low-fat milk and dairy products, but the VD subjects were asked to restrict their cheese consumption because of its high sodium content
- Usual energy recommendations were provided, but it was significantly different in dietary acid load because of the increase in the bread and cereal load and a 19mEq per day potential renal acid load (PRAL) or 12mEq per day net endogenous acid production (NEAP)
- Both groups were given the recommendation to consume monounsaturated margarine or polyunsaturated margarine and cooking oil with adjustments to meet energy requirements
- All the dietary instruction was provided by a RD
- The participants were seen on weeks two, four, eight, 12 and 14 and had telephone contact at weeks six and 10.
Statistical Analysis
- Statistical analyses were performed using SPSS version 14.0 with results represented as means ± SEM
- Randomization was stratified by BMI and use of AHT
- Differences between the two diets at baseline or during the intervention period were assessed using Student T-tests
- Paired T-tests were performed to assess changes in outcome variables from baseline to the end of the study, or changes from baseline to the intervention period
- Analysis of variance (ANOVA) with repeated measurements was used to compare the changes in BP and urinary electrolyte excretion over the 14-week study period between the two diets, and stepwise multiple linear regression analysis was used to identify predictors of BP changes
- An X2-test was performed to evaluate significant differences in proportions of subjects between the two diet groups
- All differences were considered significant if P<0.05.
- Systolic blood pressure and diastolic blood pressure: Left arm with automated TM2551 after five minutes of seated rest. Four measurements, one minute apart, were taken and average of the last three were used.
- Urinary electrolyte excretion: Two 24-hour urine collection, run-in period and four times (four, eight, 12, 14 weeks). Urinary sodium, potassium, calcium, magnesium, phosphate, creatinine and urea concentrations measured using a Randox Daytona.
- Serum lipids: Overnight fasting blood samples were collected at baseline and at weeks eight, 12 and 14 with a Hitachi 704 analyzer.
- Anthropometrics and body composition: Baseline and 14 weeks:
- Weight: Digital scale with light clothing and no shoes
- Height: Stadiometer
- Waist, hip circumference: Measured to nearest centimeter
- Total body fat: Dual energy x-ray absorptiometery.
- Vitality diet (VD): Low-sodium DASH-type diet with low dietary acid load containing six servings of 100g cooked lean red meat per week
- Reference healthy diet (RHD): Based on general dietary guidelines to reduce fat intake and increase intake of breads and cereals.
Initial N
N=111 women aged between 45 and 75 years.Attrition (Final N)
- VD: N=53 (start); final N=46 (reason subjects left the study include six that chose not to commit and one with an illness or family issues)
- RHD: N=58 (start); final N=49 (reason subjects left the study include six that chose not to commit and three with illness or family issues).
Age
- VD: Average of 60±0.7 years
- RHD: Average 58.4±0.7 years (P=0.12 for differences between groups).
Anthropometrics
Parameter | VD (N=46) | RHD (N=49) | P-value for Group Difference |
Weight (kg) | 78.0+2.0 | 79.0+1.7 | 0.71 |
Height (cm) | 162.6+1.0 | 163.1+0.9 | 0.72 |
BMI (kg/m2) |
29.5+0.7 | 29.7+4.2 | 0.79 |
Waist circumference (cm) | 97.5+1.9 | 98.2+1.6 | 0.79 |
Hip circumference (cm) | 111.4+1.4 | 111.1+1.3 | 0.86 |
Systolic blood pressure (mm Hg) | 128.3+1.6 | 126.9+1.4 | 0.52 |
Diastolic blood pressure (mm Hg) | 80.7+1.1 | 81.3+0.9 | 0.67 |
Location
Australia.
Key Findings
- Systolic blood pressure during the entire intervention was lower for the VD group as compared to the RHD (P=0.4)
- The VD group had a decrease in SBP by 5.6±1.3 mm Hg (mean±SEM) compared with a fall of 2.7±1.0mm Hg in the RHD (group difference, P=0.08)
- The change in DBP did not differ between groups
- For those taking AHT, the VD group had a greater fall in both SBP and DBP compared to the ARHD group throughout the study (repeated-measures ANOVA time by diet, both P<0.05)
- After 14 weeks of intervention, the VD group (N=17) had a significant fall of SBP (6.5±2.5mm Hg, P=0.02) and of DBP (4.6±1.4mm Hg, P=0.005), which was greater than that of the RHD group (N=18), by 5.2±2.8mm Hg SBP (group difference, P=0.08) and 3.5±1.7mm Hg DBP (P=0.05)
- Both groups had small reductions in body weight (NS between groups):
- VD: 1.1±0.3kg (P=0.001)
- RHD: 0.8±0.3kg (P=0.01).
- Weight loss explained 7% of the variance of SBP reduction (P=0.01) and 6% of DBP reduction (P=0.02); a 1kg weight loss was associated with a fall of 1.0±0.4mm Hg SBP (P=0.005) and 0.6±0.3mm Hg DB (P=0.02) with age, body weight at baseline, weight loss and change in urinary sodium included in the model
- Among subjects on AHT, a reduction in urinary sodium predicted the fall in DBP (9% variance, P=0.07) after adjustment
- Dietary acid load as measured by PRAL and NEAP was not predictive of BP responses observed in the VD or RHD group
- There was a significant difference between the groups in sodium and potassium content with a lower sodium and higher potassium excretion in the VD group as compared to the RHD
- VD, a low-sodium DASH diet with the inclusion of lean red meat on most days of the week, with a low-acid load was more effective in reducing BP in free-living post-menopausal women compared to the RHD, which was a high-carbohydrate, low-fat diet with a higher acid load
- There was a decrease in spot urine pH in the RHD group
- This effect was stronger those taking AHT
- Data from food records and diaries also reflected good compliance with the dietary recommendations.
A low-sodium DASH diet, with lean red meat on most days of the week, and low-acid load is more effective in reducing BP in older women as compared to the high-carbohydrate, low-fat diet with a higher acid load, and this effect was greater in those with AHT.
Other: | meat and livestock of Australia |
In-Kind support reported by Industry: | Yes |
The reviewer agrees with the authors conclusions. The strength of the study was the randomization that led to non-significant differences between the groups. The diet was designed to maintain body weight, which it did.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | Yes | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | Yes | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | Yes | |
5. | Was blinding used to prevent introduction of bias? | No | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | ??? | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | ??? | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | Yes | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | Yes | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |